Thomas DiRaimondo - 02 Jan 2025 Form 4 Insider Report for Janux Therapeutics, Inc. (JANX)

Role: Chief Scientific Officer
Signature: /s/ James Pennington, Attorney-in-Fact
Issuer symbol: JANX
Transactions as of: 02 Jan 2025
Net transactions value: $0
Form type: 4
Filing time: 03 Jan 2025, 20:10:06 UTC
Previous filing: 27 Sep 2024
Next filing: 02 Jan 2026
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	JANX	Common Stock	Award	$0	+24,000	+23%	$0.000000	129,719	02 Jan 2025	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	JANX	Stock option (right to buy)	Award	$0	+84,000		$0.000000	84,000	02 Jan 2025	Common Stock	84,000	$53.24	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on January 1, 2026.
F2	Includes 497 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan (the "Plan") on November 15, 2021, 1,327 shares acquired under the Plan on May 13, 2022, 1,130 shares acquired under the Plan on November 15, 2022, 1,715 shares acquired under the Plan on May 15, 2023, 763 share acquired under the Plan on November 15, 2023, 1,406 shares acquired under the Plan on May 15, 2024 and 943 shares acquired under the Plan on November 15, 2024.
F3	25% of the shares subject to the option vest on January 1, 2026 and the balance will vest in equal monthly installments thereafter over a three year period.